Ceftolozane/Tazobactam + Meropenem
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Complicated Urinary Tract Infection
Conditions
Complicated Urinary Tract Infection, Pyelonephritis
Trial Timeline
Apr 26, 2018 → Dec 3, 2020
NCT ID
NCT03230838About Ceftolozane/Tazobactam + Meropenem
Ceftolozane/Tazobactam + Meropenem is a phase 2 stage product being developed by Merck for Complicated Urinary Tract Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT03230838. Target conditions include Complicated Urinary Tract Infection, Pyelonephritis.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03230838 | Phase 2 | Completed |
| NCT02070757 | Phase 3 | Completed |
Competing Products
20 competing products in Complicated Urinary Tract Infection